A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas

Inclusion Criteria:

- Patient must be at least 18 years old

- Patient must have been diagnosed with a recurrent brain tumor by MRI scan

- Patient must be willing to practice adequate contraception

- Patient must be able to swallow the Enzastaurin tablets whole and receive Bevacizumab
intravenously

- Patient must agree to use the study drug only as instructed by your study doctor and
staff.

Exclusion Criteria:

- Women who are pregnant or breastfeeding

- Patients who have significant heart, liver, kidney, or psychiatric disease

- Patients who have an active infection

- Patients who have any recent bleeding in the brain

- Patients who are taking any anti-coagulation or anti-platelet medication (including
aspirin, non-steroidal anti-inflammatories, COX-2 inhibitors)